Literature DB >> 15867394

Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.

Salah-Eddin Al-Batran1, Mohammad-Reza Rafiyan, Akin Atmaca, Antje Neumann, Julia Karbach, Armin Bender, Eckhart Weidmann, Hans-Michael Altmannsberger, Alexander Knuth, Elke Jäger.   

Abstract

The infiltration of tumors by T cells has been shown to correlate with prolonged patients' survival. However, it remains unclear why only some tumors are infiltrated with T cells. This study was designed to investigate possible correlations between intratumoral T-cell infiltrates and the expression of cancer-associated antigens and MHC class I and II molecules in patients with melanoma. Fresh frozen samples from 124 stage IV melanoma patients were analyzed by immunohistochemistry for the expression of Melan-A/MART-1, tyrosinase, gp100, NY-ESO-1, and MHC class I and II. Intratumoral T-cell and B-cell infiltrates were detected by staining with anti-CD4, anti-CD8, anti-CD3, and L26 antibodies. The NY-ESO-1 serum antibody status was assessed by Western blot analysis. Intratumoral CD8+ and CD4+ T cells were detected in 63.9% and 71.3% of patients, respectively. We observed a significant heterogeneity of the expression of the melanocyte differentiation antigens, NY-ESO-1, and MHC class I and II molecules. The only significant correlation was found between the expression of MHC class I and the presence of CD4+ and CD8+ T cells (P < 0.0001). There was a strong association between these two variables with respect to the density and distribution of infiltrating T cells and the pattern of MHC class I expression (focal versus homogenous). Intratumoral T-cell infiltration is closely correlated with the MHC class I expression but not with the expression of differentiation antigens, cancer-associated antigens, or MHC class II molecules. These results may have implications for the definition of prognostic variables and for the identification of patients who may benefit from antigen-specific cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15867394     DOI: 10.1158/0008-5472.CAN-04-4621

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

Review 1.  Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Authors:  Francesca Maria Bosisio; Joost J van den Oord
Journal:  Virchows Arch       Date:  2017-01-05       Impact factor: 4.064

2.  Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.

Authors:  Lina Such; Fang Zhao; Derek Liu; Beatrice Thier; Vu Thuy Khanh Le-Trilling; Antje Sucker; Christoph Coch; Natalia Pieper; Sebastian Howe; Hilal Bhat; Halime Kalkavan; Cathrin Ritter; Robin Brinkhaus; Selma Ugurel; Johannes Köster; Ulrike Seifert; Ulf Dittmer; Martin Schuler; Karl S Lang; Thomas A Kufer; Gunther Hartmann; Jürgen C Becker; Susanne Horn; Soldano Ferrone; David Liu; Eliezer M Van Allen; Dirk Schadendorf; Klaus Griewank; Mirko Trilling; Annette Paschen
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

3.  4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

Authors:  Donastas Sakellariou-Thompson; Marie-Andrée Forget; Caitlin Creasy; Vincent Bernard; Li Zhao; Young Uk Kim; Mark W Hurd; Naohiro Uraoka; Edwin Roger Parra; Ya'an Kang; Christopher A Bristow; Jaime Rodriguez-Canales; Jason B Fleming; Gauri Varadhachary; Milind Javle; Michael J Overman; Hector A Alvarez; Timothy P Heffernan; Jianhua Zhang; Patrick Hwu; Anirban Maitra; Cara Haymaker; Chantale Bernatchez
Journal:  Clin Cancer Res       Date:  2017-09-25       Impact factor: 12.531

4.  Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.

Authors:  Ayman Oweida; Shelby Lennon; Dylan Calame; Sean Korpela; Shilpa Bhatia; Jaspreet Sharma; Caleb Graham; David Binder; Natalie Serkova; David Raben; Lynn Heasley; Eric Clambey; Raphael Nemenoff; Sana D Karam
Journal:  Oncoimmunology       Date:  2017-08-03       Impact factor: 8.110

5.  Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

Authors:  Elke Jäger; Julia Karbach; Sacha Gnjatic; Antje Neumann; Armin Bender; Danila Valmori; Maha Ayyoub; Erika Ritter; Gerd Ritter; Dirk Jäger; Dennis Panicali; Eric Hoffman; Linda Pan; Herbert Oettgen; Lloyd J Old; Alexander Knuth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-19       Impact factor: 11.205

6.  Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.

Authors:  Lynn T Dengel; Allison G Norrod; Briana L Gregory; Eleanor Clancy-Thompson; Marie D Burdick; Robert M Strieter; Craig L Slingluff; David W Mullins
Journal:  J Immunother       Date:  2010 Nov-Dec       Impact factor: 4.456

7.  CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Authors:  Jianda Yuan; Sacha Gnjatic; Hao Li; Sarah Powel; Humilidad F Gallardo; Erika Ritter; Geoffrey Y Ku; Achim A Jungbluth; Neil H Segal; Teresa S Rasalan; Gregor Manukian; Yinyan Xu; Ruth-Ann Roman; Stephanie L Terzulli; Melanie Heywood; Evelina Pogoriler; Gerd Ritter; Lloyd J Old; James P Allison; Jedd D Wolchok
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

Review 8.  Melanoma: oncogenic drivers and the immune system.

Authors:  Niki Karachaliou; Sara Pilotto; Cristina Teixidó; Santiago Viteri; María González-Cao; Aldo Riso; Daniela Morales-Espinosa; Miguel Angel Molina; Imane Chaib; Mariacarmela Santarpia; Eduardo Richardet; Emilio Bria; Rafael Rosell
Journal:  Ann Transl Med       Date:  2015-10

9.  Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers.

Authors:  Erica L Carpenter; Rosemarie Mick; Andrew J Rech; Gregory L Beatty; Theresa A Colligon; Myrna R Rosenfeld; David E Kaplan; Kyong-Mi Chang; Susan M Domchek; Peter A Kanetsky; Leslie A Fecher; Keith T Flaherty; Lynn M Schuchter; Robert H Vonderheide
Journal:  Clin Cancer Res       Date:  2009-06-23       Impact factor: 12.531

10.  Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.

Authors:  Bonnie E Gould Rothberg; Christopher B Moeder; Harriet Kluger; Ruth Halaban; David E Elder; George F Murphy; Alexander Lazar; Victor Prieto; Lynn McDivitt Duncan; David L Rimm
Journal:  Mod Pathol       Date:  2008-06-13       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.